Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics

被引:8
|
作者
Yuan, Heng [1 ]
Jung, Eun-Soo [2 ,3 ,4 ]
Chae, Soo-Wan [2 ,3 ,4 ]
Jung, Su-Jin [2 ,3 ,4 ]
Daily, James W. [5 ]
Park, Sunmin [1 ,6 ]
机构
[1] Hoseo Univ, Dept Bioconvergence, Asan 31499, South Korea
[2] Jeonbuk Natl Univ Hosp, Biomed Res Inst, Clin Trial Ctr Funct Foods, Jeonju 54907, South Korea
[3] Jeonbuk Natl Univ Hosp, Biomed Res Inst, Clin Trial Ctr K FOOD Microbiome, Jeonju 54907, South Korea
[4] Jeonbuk Natl Univ, Res Inst Clin Med, Jeonju 54907, South Korea
[5] Daily Mfg Inc, Dept R&D, Rockwell, NC 28138 USA
[6] Hoseo Univ, Obes Diabet Res Ctr, Dept Food & Nutr, 20 Hoseoro79 Bungil, Asan 31499, South Korea
关键词
metabolic dysfunction-associated steatotic liver disease; HFFs; gut microbiota; omics approach; HEPATIC STEATOSIS; NONCODING RNAS; DISEASE; PATHOGENESIS; CELLS; INFLAMMATION; CROSSTALK; NAFLD; NASH;
D O I
10.3390/nu16183061
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Metabolic dysfunction-associated steatotic liver disorder (MASLD) is increasingly prevalent globally, highlighting the need for preventive strategies and early interventions. This comprehensive review explores the potential of health functional foods (HFFs) to maintain healthy liver function and prevent MASLD through an integrative analysis of network pharmacology, gut microbiota, and multi-omics approaches. We first examined the biomarkers associated with MASLD, emphasizing the complex interplay of genetic, environmental, and lifestyle factors. We then applied network pharmacology to identify food components with potential beneficial effects on liver health and metabolic function, elucidating their action mechanisms. This review identifies and evaluates strategies for halting or reversing the development of steatotic liver disease in the early stages, as well as biomarkers that can evaluate the success or failure of such strategies. The crucial role of the gut microbiota and its metabolites for MASLD prevention and metabolic homeostasis is discussed. We also cover state-of-the-art omics approaches, including transcriptomics, metabolomics, and integrated multi-omics analyses, in research on preventing MASLD. These advanced technologies provide deeper insights into physiological mechanisms and potential biomarkers for HFF development. The review concludes by proposing an integrated approach for developing HFFs targeting MASLD prevention, considering the Korean regulatory framework. We outline future research directions that bridge the gap between basic science and practical applications in health functional food development. This narrative review provides a foundation for researchers and food industry professionals interested in developing HFFs to support liver health. Emphasis is placed on maintaining metabolic balance and focusing on prevention and early-stage intervention strategies.
引用
收藏
页数:22
相关论文
共 50 条
  • [1] Multi-omics analyses of the gut microbiota and metabolites in children with metabolic dysfunction-associated steatotic liver disease
    Du, Landuoduo
    Zhang, Kaichuang
    Liang, Lili
    Yang, Yi
    Lu, Deyun
    Zhou, Yongchang
    Ren, Tianyi
    Fan, Jiangao
    Zhang, Huiwen
    Wang, Ying
    Jiang, Lu
    MSYSTEMS, 2025,
  • [2] Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease
    Long, Qichen
    Luo, Fengming
    Li, Binghui
    Li, Ziyang
    Guo, Zhe
    Chen, Zhiyang
    Wu, Weimin
    Hu, Min
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (03)
  • [3] Dietary Influences on Gut Microbiota and Their Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Hamamah, Sevag
    Iatcu, Oana C.
    Covasa, Mihai
    NUTRIENTS, 2025, 17 (01)
  • [4] Metabolic dysfunction-associated steatotic liver disease and gut microbiota
    Petryna, Vitalii
    JOURNAL OF HEPATOLOGY, 2024, 80 : S285 - S285
  • [5] Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Scarpellini, Emidio
    Scarcella, Marialaura
    Tack, Jan F.
    Scarlata, Giuseppe Guido Maria
    Zanetti, Michela
    Abenavoli, Ludovico
    ANTIOXIDANTS, 2024, 13 (11)
  • [6] Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease (MASLD) (vol 8, e0310, 2024)
    Long, Q.
    Luo, F.
    Li, B.
    Li, Z.
    Chen, Z.
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (07)
  • [7] Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Zazueta, Alejandra
    Valenzuela-Perez, Lucia
    Ortiz-Lopez, Nicolas
    Pinto-Leon, Araceli
    Torres, Veronica
    Guinez, Danette
    Aliaga, Nicolas
    Merino, Pablo
    Sandoval, Alexandra
    Covarrubias, Natalia
    Perez de Arce, Edith
    Cattaneo, Maximo
    Urzua, Alvaro
    Roblero, Juan Pablo
    Poniachik, Jaime
    Gotteland, Martin
    Magne, Fabien
    Beltran, Caroll Jenny
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (08)
  • [8] ALTERED GUT VIRAL ECOLOGY IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Nzabarushimana, Etienne
    Kim, Hanseul
    Jensen, Jordan
    Shen, Jiaxian
    Nelson, Paul
    Thompson, Kelsey N.
    Chan, Andrew T.
    Hayete, Boris
    Huttenhower, Curtis
    Nguyen, Long H.
    GASTROENTEROLOGY, 2024, 166 (05) : S1539 - S1540
  • [9] THROMBOSPONDIN 2: A KEY PLAYER IN FIBROGENESIS OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE UNCOVERED BY MULTI-OMICS ANALYSIS
    Kimura, Takefumi
    Wakabayashi, Shun-Ichi
    Tanaka, Naoki
    Umemura, Takeji
    HEPATOLOGY, 2024, 80 : S569 - S570
  • [10] USEFULNESS OF SERUM MICRORNAS AS BIOMARKERS FOR PEDIATRIC METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
    Blakley, Caroline
    Nelson, Benjamin
    Qarooni, Shatha
    Lee, Wai Han
    Tryggestad, Jeanie
    Short, Kevin
    Palle, Sirish Kumar
    HEPATOLOGY, 2024, 80 : S626 - S626